Work

Telomere dynamics and chemotherapy in aging and cancer

Year: 2005
Type: dissertation
Abstract: BACKGROUND ………………………………………………………………. 2 A) Telomere structure and function………………………………….…... 2 B) Telomerase function and regulation……………………………….….. 4 C) Cellular senescence…………………………………………………….. 5 D) Telomere length variation and attrition……………………………… 9 E) Telomeres and disease……………………………………………….… F) DNA damage and repair……………………………………………….G) Chemotherapeutics and treatment……………………………………. H) Chemotherapeutics and telomeres………...………………………….. III.OBJECTIVES……………………………………….………………………….IV.MATERIALS AND METHODS…………………….………………………... A) Cell Culture……………………………………..……………………… B) Chemotherapeutic treatment in vitro…………..…………………….. C) Cytotoxicity assay……………………………..……………………….. D) β-galactosidase assay…………………………..……………………….E) Cell Cycle distribution and apoptosis assay…..…..………………….. F) Western blotting…………………………………..…………………….G) Patient Selection and Treatment…………………..………………….. H) Lymphocyte and DNA preparation………………..………………….I) Terminal Restriction Fragment analysis…………..………………….J) Labeling of the telomere probe and molecular weight marker…..….K) Telomere length and statistical analysis…………………………..….. V. RESULTS……………………………………………………………………….. Part 1: Telomere length variation in human primary cells treated with chemotherapeutic agents…………………………………….… vi A) Viability differences in cells based on the chemotherapeutic drug concentration………………………………… B) Drug-induced cell cycle progression and cell patterns in normal and NER-deficient fibroblasts……………………………… C) Morphological changes and senescence-associated β-Galactosidase expression in fibroblasts after platinum treatment………………………………………………..…….D) Expression of senescence-associated proteins after chemotherapeutic treatment………………………………………….... E) Telomere length changes in fibroblasts due to platinum treatment……………………………………………...……… Part 2: Telomere length variation in humans and chemotherapy……..….A) Age and gender difference in the rate of telomere length loss…….…B) Telomeres in the blood cells of head and neck cancer patients compared to those in a control population …….……………..……… C) The shortening of telomere length throughout chemoradiotherapy treatment in head and neck cancer……..……... VI.DISCUSSION………………………………………………………...………….Part 1: Variation in telomere length after chemotherapeutic treatment in vitro……………………………………………………..……….A) Sensitivity to treatment with anticancer agents varies between fibroblast strains ……..……………………………….. B) G2/M accumulation in platinum treated fibroblasts ……………..….C) Platinum-induced senescence-like phenotype in fibroblasts …….….. D) Altered levels of specific proteins in fibroblasts due to platinum ……………………………………………………………....… E) Telomere length reduction following long-term platinum treatment……………………………………………….….….Part 2: Variation in telomere length in the population and during chemotherapy…………………………………………….…….... A) Population variation in the rate of telomere shortening………..….. B) Similar telomere lengths in head and neck cancer patients and controls…………………………………………………………..….C) Telomere shortening throughout chemoradiotherapy treatment…………………………………………………………….….VII.CONCLUSIONS………………………………………………………….…….. VIII.BIBLIOGRAPHY………………………………………………………….…...
Language: English
Subfield: Cell Biology
Open Access status: green
OpenAlex ID: W2555643668
Cites: 185
Cited by:
Related to: 10